Genentech Inc. said slower than expected growth...

Genentech Inc. said slower than expected growth in the market for clot-dissolving treatments for heart attacks will affect the company’s third-quarter results. The slowed growth in the market, combined with the implementation in June of a special program to ensure that small community hospitals stock Activase, its clot-dissolving drug, will reduce third-quarter sales by about 20% from the second quarter, said Robert A. Swanson, Genentech’s chief executive. The firm expects to report earnings of about 6 cents a share, unchanged from a year earlier.